Abstrakti
Background: The effects of radiotherapy (RT) patients’ health-related quality of life (HRQoL) are usually compared to those of other treatment modalities instead of HRQoL of the general population in oncological studies. We examined HRQoL of patients with an early prostate cancer (PC) not receiving hormonal treatment up to 3 years after RT using the 15D instrument and the FACT-P questionnaire. Methods: The 15D results were compared to those in the age-standardized general male population (N = 952) using an independent-sample t test. The study population (N = 73) received RT either with 78/2 Gy, 60/3 Gy or 36.25/7.25 Gy fractionation. Results: No significant differences in the mean total HRQoL scores were found between the RT groups and the general male population at any time point. Patients with PC had more depression (P = .015) and distress (P = .029) than the general male population before the treatment and depression up to 3 months after treatment (P = .019), which did not persist at 3 years. The sexual activity dimension had declined by the end of treatment, and this decline persisted 3 years later (P = .033). Excretion functions were worse compared to those in peers at the end of treatment (P < .001) but no longer at 3 months and later after RT. Regarding the FACT-P, HRQoL remained good at 3 years after RT in all the treatment groups and there were no significant differences between the different RT groups at this time point. Conclusion: This study demonstrated that patients treated with RT for early PC had similar HRQoL compared to the age-standardized general male population at 3 years after treatment.
Alkuperäiskieli | Englanti |
---|---|
Sivut | 146-154 |
Julkaisu | CLINICAL GENITOURINARY CANCER |
Vuosikerta | 21 |
Numero | 1 |
Varhainen verkossa julkaisun päivämäärä | 2022 |
DOI - pysyväislinkit | |
Tila | Julkaistu - 2023 |
OKM-julkaisutyyppi | A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä |
Rahoitus
To Irja Kolehmainen, research coordinator and research nurses Tuula Nuuttila and Jasmin Salmi. This research was funded by Seppo Nieminen foundation, Grant number 15012, Tampere University Hospital and by the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital, Grant numbers 9V019, 9AA027, 9AB027 and 9U020, Tampere University Hospital.
Julkaisufoorumi-taso
- Jufo-taso 1
!!ASJC Scopus subject areas
- Oncology
- Urology